sr141716 has been researched along with Nausea in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anthenelli, RM; Aubin, HJ; Cinciripini, PM; Dale, LC; Karam-Hage, M; Niaura, R; Robinson, JD | 1 |
| Duncan, M; Parker, LA; Rock, EM; Sticht, MA; Stott, C | 1 |
| Bottegoni, G; Limebeer, CL; O'Brien, LD; Parker, LA; Piomelli, D; Rock, EM | 1 |
| Abdullah, RA; Imhof, E; Lichtman, AH; Limebeer, CL; Parker, LA; Rock, EM; Wang, K | 1 |
| Abbott, L; Burton, P; Fudge, ML; Mechoulam, R; Parker, LA; Schlievert, C | 1 |
| Cahill, K; Ussher, M | 2 |
2 review(s) available for sr141716 and Nausea
| Article | Year |
|---|---|
Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation.
Topics: Adult; Body Weight; Depression; Humans; Nausea; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Receptor, Cannabinoid, CB1; Rimonabant; Secondary Prevention; Smoking Cessation; Smoking Prevention; Suicide | 2007 |
Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation.
Topics: Adult; Body Weight; Depression; Humans; Nausea; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Receptor, Cannabinoid, CB1; Rimonabant; Secondary Prevention; Smoking; Smoking Cessation; Smoking Prevention; Suicide | 2007 |
1 trial(s) available for sr141716 and Nausea
| Article | Year |
|---|---|
Pooled analysis of three randomized, double-blind, placebo controlled trials with rimonabant for smoking cessation.
Topics: Adult; Anorexia; Anxiety; Cannabinoid Receptor Antagonists; Cigarette Smoking; Diarrhea; Double-Blind Method; Female; Humans; Male; Middle Aged; Nausea; Rimonabant; Smoking Cessation; Vomiting | 2018 |
4 other study(ies) available for sr141716 and Nausea
| Article | Year |
|---|---|
Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ(9) -tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats.
Topics: Animals; Behavior, Animal; Cannabinoid Receptor Agonists; Cannabinoids; Disease Models, Animal; Dronabinol; Drug Partial Agonism; Lithium Chloride; Male; Nausea; Phytochemicals; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant | 2013 |
Anandamide transport inhibition by ARN272 attenuates nausea-induced behaviour in rats, and vomiting in shrews (Suncus murinus).
Topics: Amidohydrolases; Animals; Antiemetics; Arachidonic Acids; Behavior, Animal; Biological Transport; Cannabinoid Receptor Antagonists; Disease Models, Animal; Dose-Response Relationship, Drug; Endocannabinoids; Isoenzymes; Lithium Chloride; Male; Nausea; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant; Shrews; Vomiting | 2013 |
Attenuation of anticipatory nausea in a rat model of contextually elicited conditioned gaping by enhancement of the endocannabinoid system.
Topics: Amidohydrolases; Animals; Anticipation, Psychological; Arachidonic Acids; Brain; Cannabinoid Receptor Antagonists; Carbamates; Endocannabinoids; Enzyme Inhibitors; Glycerides; Indoles; Lithium Chloride; Male; Monoacylglycerol Lipases; Motor Activity; Nausea; Oleic Acids; Piperazines; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant | 2014 |
Effects of cannabinoids on lithium-induced conditioned rejection reactions in a rat model of nausea.
Topics: Animals; Antiemetics; Avoidance Learning; Behavior, Animal; Cannabinoids; Conditioning, Psychological; Disease Models, Animal; Dose-Response Relationship, Drug; Dronabinol; Lithium; Male; Nausea; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Rimonabant | 2003 |